Register (On-Demand) • Schedule

AAPP 2024 Scientific Poster Session Abstracts

Below is a complete list of the posters that will be presented at AAPP 2024. There will be two different poster sessions, and award finalists will present their posters on the same day as their platform presentation.

Click on the column headings to sort the table below, or click on a keyword next to a poster to filter by specific topic.

Use the search box to quickly locate an abstract by any data in the column, including "PGY2"! The site search provides full-text search of all 3,500+ abstracts that have been presented at the AAPP Annual Meeting over the years.

Title
'Tranq’: Perceptions of Xylazine and Harm Reduction Practices Among People Receiving Treatment for Substance Use Disorders
"Escaping Addiction: Creating a Path to Recovery": a novel escape room game
A Comparative Analysis of Metabolic Monitoring for Second Generation Antipsychotics (SGAs) in an Outpatient Psychiatry Clinic for Patients with and without Pharmacist Co-Management
A Managed Healthcare Integrated Care Program for Severe Mental Illness (SMI)
A Novel Advanced Pharmacy Practice Experience (APPE): Scientific Writing with a Focus in Psychiatric Pharmacotherapy
A Pharmacist-Driven Therapeutic Drug Monitoring Program for Mood Stabilizers
A Retrospective Review of Changes in Rate of Psychosis - Related Inpatient Psychiatric Admissions and Recent Stimulant Prescriptions at a Non-Profit Psychiatric Facility
A Student-led, Free Clinic Provides Access to Naloxone In An Underserved Population
Acute Suicidal Ideation and Thoughts of Self-harm with Valbenazine
Alcohol Use Relapse Rates for Patients with Liver Transplants in Early vs Standard Transplant Timeline
Alice in Wonderland Syndrome Associated with Topiramate
An Outpatient Pharmacist Consultation Service to Help Address a Psychiatry Waitlist Crisis: Protocol for Implementation and Program Evaluation
Analysis of Anxiety, Stress, and Depression Trends in Pharmacy Students Pre- vs Post- Pandemic
Analysis of Experiential Education Absence Policies for Mental Health Criteria
Anticholinergics are Not Appropriate Treatments for Tardive Dyskinesia: Insights from an Expert Panel of Psychiatry and Neurology Healthcare Professionals
Antipsychotic-Induced Muscle-Specific Tyrosine Kinase (MuSK) Antibody Positive Myasthenia Gravis
Antipsychotic-induced Tics in Autism Spectrum Disorder
Are REM Biomarkers Appropriate for Assessing Clinical Improvement in Major Depressive Disorder?
Assessing Acute Agitation Management at a Federal Health Care Center
Assessing Documentation of Clozapine Trials in Patients Prescribed Antipsychotic Polypharmacy Regimens at Discharge
Assessing the Applicability of Drug-Related Concentration (DRC) Factors for Antipsychotics in Forensic Psychiatric Patients
Assessing the Impact of an Innovate Behavioral Health Urgent Care Clinic
Assessment of Clozapine Therapeutic Drug Monitoring
Assessment of Long-Acting Injectable Antipsychotic Use and Hospital Readmissions After a Pilot Formulary Expansion
Assessment of Psychiatric Patients’ Actual QTc Intervals vs. Predicted QTc Prolongation Risk
ATLAS - Addiction Treatment: Linking Access & Services Mobile Clinic Reducing Stigma-related Barriers in Rural NC
Baseline demographics and clinical characteristics from OASIS: Observational Study of Long-Acting Injectables in Schizophrenia
Behavioral Health Agitation Protocol Impact on As Needed Medication Use
Buprenorphine Micro-induction and Bridge Dosing Outcomes
Burnout Assessment of Pharmacy and Physician Assistant Program Students at a Historically Black College and University (HBCU)
Burnout Assessment of Pharmacy Faculty at a Historically Black College and University (HBCU)
Changes in Attitudes and Behaviors Associated with Buprenorphine Best Practices Dissemination
Characterization of Flumazenil Utilization in Electroconvulsive Therapy
Cheers to Well-Being: Exploring the Impact of a Peer Support Program on Pharmacy Student Resilience and Happiness
Clinical Pharmacist Efforts to Increase Access to Buprenorphine in Veteran Population
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants
Clozapine-Induced Neutropenia in the Management of Treatment-Resistant Schizophrenia: A Case Report
Clozapine, Caffeine, and Smoking: a Correlational Study and Initiation of Pharmacist‐Led Interventions to Improve Clinical Outcomes
Comparing Buprenorphine Prescription Patterns for Opioid Use Disorder (OUD) Before and After the Drug Addiction Treatment Act (DATA)-waiver Removal at a Hospital Healthcare System
Comparing Effectiveness Between Different Antidepressants in Preventing Psychiatric Rehospitalization
Comparing the Cognitive Effect of Vortioxetine versus Other Selective Serotonin Receptor Inhibitors
Comparison of High-Dose Olanzapine and Standard-Dose Olanzapine in Adult Patients at a County Psychiatric Hospital: A Retrospective Study
Comparison of Kloxxado® and Narcan® Usage Following Updates to Computerized Patient Record System
Comparison of Pharmacist-Led Outpatient Depression Management to Current Prescriber-Led Depression Management
Comparison of Rehospitalization Outcomes in the Veteran Population Administered Long-acting Injectable Naltrexone Versus Oral Naltrexone for Alcohol Use Disorder Before Discharge
Comparison of Treatment Outcomes in the Veteran Population Administered Aripiprazole Long-acting Injectable Versus Paliperidone Palmitate Long-acting Injectable for Bipolar Disorder in the Inpatient Setting
Correlation Between Higher Screen Time and Decreased Quality of Life in General Adolescents; An Analysis of YRBS Data from CDC
Database Analysis for the Concomitant Use of an Immediate-Release Stimulant with an Extended-Release Stimulant for the Treatment of ADHD
Development and Validation of an Instrument to Assess Patient Experience of Pharmacist-led Patient Medication Education Groups
Do Discharge Medications Prevent Rehospitalization Following Short-Term Crisis Stabilization at a County Psychiatric Hospital?
Does Patient Attitude Toward Psychiatric Drug Therapy Impact Adherence to Their Medications?
Duloxetine for Treatment Resistant Depression in Older Adults
Effect of Clozapine for Depressive Symptoms in Black Patients with Schizophrenia or Schizoaffective Disorders
Effectiveness of Tetrabenazine for the Treatment of Antipsychotic-induced Tardive Dyskinesia
Efficacy of KarXT (Xanomeline and Trospium) in Schizophrenia: Pooled Results From the Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials
Efficacy of Lumateperone in Pooled Short-Term Late-Phase Clinical Trials for Treatment of Major Depressive Episodes Associated With Bipolar II Disorder
Efficacy, Tolerability, and Safety of AXS-05, a Novel Oral Antidepressant: Data From 3 Clinical Trials
Eliminating Drug Cost as Barrier to Medication Access
Emergency Room (ER) Visits Among Opioid Use Disorder (OUD) Patients
Enhancing Buprenorphine Access and Identifying Treatment Barriers in Veterans with Opioid Use Disorder
Establishing a Database to Examine the Real-World Impact of Psychiatric Pharmacogenomic Testing in a Large Health System
Establishing a Pharmacist-Run, Outpatient Long-Acting Injectable Antipsychotic Clinic in a Safety Net Hospital
Establishing Monitoring Standards for Medication Therapy for Adults with Attention Deficit Hyperactivity Disorder (ADHD)
Establishment of Behavioral Health Pharmacy Service Line at a Rural, Critical Access Indian Health Service Hospital System
Evaluating Outcomes of Psychotropic Drug Safety Initiative (PDSI) Management System for Management of Stimulant Use at a Medical Center
Evaluating the Impact of an Automated Phone Outreach Program on Naloxone Prescribing to Veterans At-Risk for Opioid Overdose
Evaluating the Impact of Photovoice on Self-Stigma Levels Among Individuals with Substance Use Concerns
Evaluating the Impact of Pre- and Post-Exams on Psychiatry Pharmacy Student Rotations: A Comprehensive Analysis
Evaluating the Occurrence of Mania-Related Hospitalizations in Patients with Bipolar Disorder or Schizoaffective Disorder Receiving Antidepressant Therapy
Evaluating the Use of a Pharmacist Led Initiative in Reducing Anticholinergic Burden at a State Psychiatric Hospital
Evaluation of Aripiprazole in the Treatment of Food Avoidant Behaviors among Adolescents with Anorexia Nervosa
Evaluation of Behavioral Health Pharmacy Advocates (BHPA), a Training Program for Pharmacy Personnel
Evaluation of Bupropion Renal Dose Adjustment at an Inpatient Mental Health Facility to Optimize Patient Outcomes
Evaluation of Current Valproic Acid Monitoring Practices in Inpatient Psychiatric Settings
Evaluation of EKG Monitoring for Citalopram and Escitalopram
Evaluation of Intentional Overdose Trends among Youth in Pennsylvania Before and During the COVID-19 Pandemic
Evaluation of Lithium Utilization at an Inpatient Mental Health Facility to Optimize Patient Outcomes
Evaluation of Medication Assisted Treatment (MAT) Program Enrollment and Treatment Retention, pre and post Drug Addiction Treatment Act (DATA) Waiver Elimination
Evaluation of Pharmacy Resident Burnout and Career Satisfaction Based on Residency Staffing Model
Evaluation of the Impact of Concomitant Valproic Acid and Lorazepam Administration on Sedation
Evaluation of Treatment for Mania in Veterans with Bipolar I Disorder
Evaluation of Workload and Burnout Among Psychiatric Pharmacists in the United States
Examining The Correlation Between Follow-Up After Opioid Overdose And Clinical Outcomes At Los Angeles General Medical Center
Examining the Interventions of an Interdisciplinary Overdose Review Team (ORT) at a Rural Veterans Affairs Medical Center
Expanding Buprenorphine Access in a Primary Care Setting at an Ambulatory Outpatient Clinic
Exploring the Harm Reduction Paradigm: The Role of Board-Certified Psychiatric Pharmacists
Exploring the Impact of Oral Antidepressant Class Selection on Esketamine-Treated Patients with Treatment-Resistant Depression
Exploring the Need for Weight Loss Interventions in Clozapine Patients at a Veterans Affairs Healthcare System
Exploring the Potential Efficacy of Medical Cannabis for Major Depressive Disorder: A Systematic Review
Extent, patterns and predictors of contraception use among women of child-bearing age prescribed valproic acid in the United States
Formation of a Working Alliance and Efficacy of a Digital Therapeutic to Treat Experiential Negative Symptoms of Schizophrenia
From Mute to Multilingual: Successful Treatment of Benzodiazepine-Refractory Chronic Catatonia with Memantine
Glucagon-Like Peptide-1 Receptor Agonists and Risk for Depression Relapse
Healthcare Resource Utilization Following 6 Months of Treatment With Olanzapine/Samidorphan: Real-World Assessment of Patients With Schizophrenia or Bipolar I Disorder
High-Dose Vilazodone for the Treatment of Major Depressive Disorder: A Case Report
Hit Me with Your Best Shot: Implementation and Evaluation of Clinical Pharmacist Impact within a Long-Acting Injectable Antipsychotic Clinic at a Veterans Affairs Medical Center
Impact of Antipsychotic Therapeutic Drug Monitoring (TDM) In a Mental Health Intensive Case Management Team
Impact of AXS-05, an Oral NMDA Receptor Antagonist and Sigma-1 Receptor Agonist, on Anhedonic Symptoms in Major Depressive Disorder
Impact of Clinical Pharmacist Intervention on a Neuropsychiatry and Behavioral Neurology Consult Service at a Free-standing Psychiatric Hospital
Impact of Combinatorial Pharmacogenomic Testing on Hospitalization Rates in a Real-World Dataset of Patients with Major Depressive Disorder
Impact of Medication Reviews by Pharmacists in Veterans Flagged High Risk for Suicide
Impact of MH PGY2 Pharmacy Resident Outreach to Veterans with Potentially Untreated Opioid Use Disorder Recently Discharged from the Emergency Department
Impact of Paroxetine 2D6 Inhibition in a Patient Transitioned From Oral Risperidone to Paliperidone Palmitate: A Case Report
Impact of Pharmacist Administration of Long-Acting Injectable Antipsychotics in Community Pharmacies
Impact of Pharmacist Intervention on Appropriate Prescribed Stimulant Monitoring Among Veterans
Impact of Pharmacist Led Contingency Management in Patients with Substance Use Disorders
Impact of Pharmacist-driven Intervention to Improve Long-acting Injectable Paliperidone Palmitate Administration and Ordering
Impact of Pharmacist-led Ambulatory Alcohol Detoxification
Impact of Pharmacist-Led Intervention in Veteran Patients With Positive Alcohol Use Disorder Identification Test on Access to Care and Clinical Metrics
Impact of the Stimulant Shortage on Prescribing Patterns in a Child and Adolescent Psychiatry Outpatient Clinic
Impact of Viloxazine Extended-Release Capsules on Self-Rated Executive Function in a Long-Term, Phase 3, Open-Label Extension Trial of Adult ADHD
Impacts of COVID-19 Events on Clozapine Therapeutics: A Case Report
Implementation and Impact of Psychotropic Stewardship at a Large Academic Medical Center
Implementation of a Pharmacist Driven Long-Acting Injectable Antipsychotic Transitions of Care Service
Implementation of A Pharmacist-Driven Long-Acting Injectable Antipsychotic Stewardship Program at VA Sierra Nevada Health Care System
Implementation of a Pharmacist-led Mental Health Transitions of Care Clinic for Patients Discharged from a Residential Rehabilitation Treatment Program
Implementation of a Standardized Buprenorphine/Naloxone Induction Protocol on an Inpatient Psychiatry Unit
Implementation of mMINDS Monitoring for Alcohol Withdrawal at an Academic Psychiatric Facility
Improving the Utilization of Long-Acting Injectable Antipsychotics in Eligible Veterans at a Veterans Affairs Outpatient Health Care System
Improving Veteran No-Show Rates at an Outpatient Mental Health Clinic Through Implementation of Measurement-Based Care Reminders
Increase Access to Naloxone for Veterans Enrolled in Home Based Primary Care
Influence of Patient Gender on Antipsychotic Selection in an Acute Inpatient Setting
Integration of a Clinical Pharmacist into Geriatric Psychiatry Treatment Team within a Veterans Affairs Healthcare System
Integration of a Psychiatric Clinical Pharmacist Practitioner into a Virtual Long-Term Opioid Therapy Reassessment Clinic
Investigating Presence of Race Based Prescribing Differences in Hospitalized Patients Starting Buprenorphine using Transdermal Patch Micro-induction Method
Investigating the Inhibitory Effects of Cannabis Smoke Condensate on Cytochrome P450 in the Human Lung
Investigation of the Effects of Medication Adherence on Hospital Admission
Involvement in Pediatric Psychiatry Pharmacy Intern Shift Improves Self-Efficacy/Comfort
Kratom: A Veteran’s Ally or Adversary?
Lithium and Antipsychotics in Post-Partum Psychosis: Utilization of Pro re Nata Medications on an Inpatient Psychiatric Perinatal Unit
Long Acting Injectable Antipsychotic Use and Discontinuation Rates in Pediatric Patients Using Medicaid Claims Data
Long-Acting Injectable Antipsychotic Use in Pediatric and Adolescent Patients with Psychiatric Disorders
Long-term Follow-up of Implementation of Psychotropic Medication Utilization Parameters for Children and Adolescents in Texas Foster Care
Long-Term Metabolic Outcomes associated with KarXT (Xanomeline and Trospium): Interim Results from Pooled, Long-Term Safety Studies EMERGENT-4 and EMERGENT-5
Lumateperone Treatment for Major Depressive Episodes with Mixed Features in Major Depressive Disorder and Bipolar I or Bipolar II Disorder
Managing Prescription Assistance Program Discontinuation at a Certified Community Behavioral Health Clinic
Medication Use Evaluation of Micro-Induction of Buprenorphine-Naloxone in a Stepped Care Model
Mental and Behavioral Health Supports and Services Provided by Pharmacists in Washington State
Mental Healthcare Utilization Among Transgender Individuals in a Community Psychiatric Hospital
Naloxone Education Program Initiative in FMC, Devens
Opioid Treatment Programs, Healthcare Resource Utilization, and Healthcare Costs among patients initiating treatment with Buprenorphine Extended-Release
Overdose Prevention Strategies in High-Risk Youth Populations; Impact of Pharmacist-Driven Intervention and Interprofessional Collaboration
Patients Requiring Early Administration of Maintenance Long-Acting Injectable Antipsychotic Dose
Pharmacist Managed Anxiety and Depression Treatment at a Federally Qualified Health Center
Pharmacist Run Pharmacotherapy Clinic Utilizing Behavioral Health Intervention Billing
Pharmacist-Led Intervention To Improve Adherence of Antidepressants and Address Potential Barriers Using Population Health Dashboard at a Rural Veterans Hospital
Pharmacist-Provided Education on Antipsychotic Monitoring Parameters after the COVID-19 Pandemic
Pharmacists’ Attitudes Towards Psychedelics and their use in Therapy
Pharmacokinetics of Viloxazine ER (Viloxazine Extended-Release Capsules) in Breastmilk of Healthy Lactating Women
Pharmacy Students Advancing Mental Health Equity in an Underserved Racial/Ethnic Community
Prescribing Patterns of Valproic Acid and Derivatives in Nursing Home Residents with Dementia
Prevalence of Asymptomatic Bacteriuria in Psychiatric Patients at a County Safety Net Hospital
Protocol Deviations of Inpatient Medication Order Adjustments Associated with Electroconvulsive Therapy
Providing Targeted Outreach for Pharmacogenomic Testing to Actionable Veterans with Post Traumatic Stress Disorder (PTSD)
Psychotropic Prescribing Patterns Among Forensic Psychiatric Inpatients with and without Borderline Personality Disorder
Psychotropic Stewardship: Review of Antipsychotic Polypharmacy at Discharge from a Free-standing Psychiatric Hospital
Quality Improvement for Pediatric Opioid, Benzodiazepine, and Alcohol Detoxification Treatment through Development and Implementation of a Standardized System Wide Protocol
Re-Evaluation of Stimulant Prescribing Patterns of Veterans Affairs Outpatient Mental Health Providers: A Five-Year Follow Up Study
Real-World Clinical Experience of Dexmedetomidine Sublingual Film for Agitation in Adults with Schizophrenia or Bipolar Disorder
Relapse Rates Among Veterans on Maintenance Doses of Oral Buprenorphine/Naloxone versus Subcutaneous Extended-Release Buprenorphine for Opioid Use Disorder
Relevance of Psychiatry-Focused Pharmacogenomic Test Results to Non-Psychiatric Medications Treatment In Pediatric and Adult Patients
Retrospective Review of Patients’ Receiving Long-Acting Injectables on Inpatient Behavioral Units to Assess the Impact of Pharmacist Led Administration in Outpatient and Retail Settings
Role of Board-Certified Psychiatric Pharmacists in Child and Adolescent Psychiatry
Safety and Tolerability of KarXT (Xanomeline and Trospium): Pooled Results From the Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials
Standardizing the Inpatient Medication Reconciliation Process for Long-Acting Injectable Antipsychotics
Student Perceptions of Relaxation Before And After Exposure to Relaxation Tools And Techniques
Switching Patients With Schizophrenia to TV-46000, a Long-Acting Subcutaneous Antipsychotic (LASCA), From Risperidone Microspheres (R064766): An Exploration of Population Pharmacokinetic (PopPK)–Based Strategies
The Effect of Mental Health Clinical Pharmacy Specialist Intervention on Cardiovascular Safety and Urine Drug Screen Monitoring for Patients Prescribed Stimulants at the Cincinnati Veterans Affairs Medical Center
The Effect of Montelukast on Suicidal Ideation in the Veteran Population
The Impact of Long-Acting Injectable Antipsychotic Therapies Versus Oral Antipsychotic Therapies on Adherence and Clinical Outcomes
The Importance of Incorporating Drug-Drug Interactions and Lifestyle Factors in Pharmacogenomics-Guided Medication Management for Patients with Major Depressive Disorder in a Randomized Controlled Trial  
The Role of Social Media on Dissemination of Information Regarding Antidepressants
The Safety And Efficacy of Antidepressants As An Alternative Therapy In The Treatment Of ADHD In Pediatric Populations: A Review Of The Literature
Transition of Veterans with Mental Health Disorders from Mental Health Clinic to Primary Care Clinic
Treatment and Economic Challenges when Treating Patients with Agitation Associated with Schizophrenia or Bipolar Disorder in the Emergency Department (ED)
Treatment Engagement of Patients Initiated on Extended-Release Injectable Naltrexone for Alcohol Use Disorder in the Inpatient Setting
Treatment Patterns and Healthcare Resource Utilization Following Initiation of Aripiprazole Lauroxil Using a 1-Day Initiation Regimen
Treatment patterns and outcomes from OASIS: Observational Study of Long-Acting Injectables in Schizophrenia
Treatment Resistant Priapism in a 61-Year-Old Male After Combined Use of Trazodone, Quetiapine, and Fluoxetine.
Trends in the Use of Co - Prescribed Benzodiazepines and Opioids in the United States: 2011 - 2020
Unveiling Stigma in Healthcare: An Exploration of Student Pharmacists’, Nurses’ and Physicians’ Attitudes Towards Mental Illness
Utility of a Clinical Pharmacist Practitioner in the Deprescribing of Z-hypnotics in Older Adults
Utilization of Lidocaine/Epinephrine to Minimize Injection Site Pain for Patients Receiving Subcutaneous Extended-Release Buprenorphine
Utilizing Therapeutic Drug Monitoring to Optimize Dosing of Antipsychotics on Inpatient Behavioral Health Units
Viloxazine ER Administered with Psychostimulants in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Results of a Phase IV Safety Trial
Zuranolone and Brexanolone: A Review of Novel Treatment Options for Moderate to Severe Postpartum Depression